Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

Gilead Sciences has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the US and some other developed countries. The price for a single vial has been set at $390. The price for US private insurance companies will be $520 per vial. The Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals.

pennydreadful
pennydreadful
Rose
Rose 1 weeks

And, knowing hospitals like I do, they will raise the price per patient/per shot, to the price of a full vial.

justin
justin 1 weeks

It’s cool we’re giving other countries better prices. We need to pay more because reasons.

Doug
Doug 1 weeks

Newsweek: "A five-day remdesivir treatment for the novel coronavirus will cost private insurance companies $3,120 per patient versus $2,340 for those using government programs." IMHO, yet another strong argument for single-payer #MedicareForAll.

Mary
Mary 1 weeks

This is obscene! I knowit is expensive to research and develop medications but does ANYBODY really think the average American with Covid 19 canafford the treatment. Get real!

RainMarvel
RainMarvel 1 weeks

This is just the suggested price. Even you dont have ro pay it. It will be paid by the insurance company. Also this is the price of Giving the does and the entire treatment,not the price of drug. Quit reasonable.

Top in U.S.
Get the App